Inventor · disambiguated record
Bette T. Korber
Also filed as: KORBER BETTE · KORBER BETTE T · KORBER BETTE T M
41 granted patents·13 pending applications·246 citations·filing 2002–2024
97Inventor score
Files withUNIV DUKE22LOS ALAMOS NAT SECURITY LLC6BETH ISRAEL DEACONESS MEDICAL CT INC5KORBER BETTE T5VIR BIOTECHNOLOGY INC4
Top patents by PatentIndex Score
54 records- 0196US7951377B2Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogensLOS ALAMOS NAT SECURITY LLC·Filed 2008·Granted May 31, 2011·37 cites·6 claims
- 0293US9017691B2Antiviral vaccines with improved cellular immunogenicityBAROUCH DAN H·Filed 2009·Granted Apr 28, 2015·50 cites·23 claims
- 0392US10149902B2Swarm immunization with envelopes from CH505UNIV DUKE·Filed 2015·Granted Dec 11, 2018·7 cites·20 claims
- 0489US10894078B2HIV vaccines comprising one or more population episensus antigensVIR BIOTECHNOLOGY INC·Filed 2015·Granted Jan 19, 2021·4 cites·26 claims
- 0589US8119140B2Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteinsKORBER BETTE T·Filed 2006·Granted Feb 21, 2012·12 cites·7 claims
- 0689US8071107B2Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteinsHAYNES BARTON F·Filed 2004·Granted Dec 6, 2011·26 cites·8 claims
- 0788US9011875B2Human immunodeficiency virus type 1 clade M mosaic gag polypeptidesKORBER BETTE T·Filed 2012·Granted Apr 21, 2015·5 cites·6 claims
- 0887US9011873B2Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogensKORBER BETTE T·Filed 2011·Granted Apr 21, 2015·4 cites·18 claims
- 0987US7195768B2Polyvalent immunogenUNIV CALIFORNIA·Filed 2003·Granted Mar 27, 2007·23 cites·9 claims
- 1087US7172761B2Polyvalent immunogenUNIV CALIFORNIA·Filed 2003·Granted Feb 6, 2007·18 cites·9 claims
- 1186US9670253B2Antiviral vaccines with improved cellular immunogenicityBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2015·Granted Jun 6, 2017·4 cites·20 claims
- 1286US9044445B2Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogensKORBER BETTE T·Filed 2009·Granted Jun 2, 2015·4 cites·18 claims
- 1385US9492532B2Nucleic acids encoding mosaic HIV-1 gag proteinsUNIV DUKE·Filed 2015·Granted Nov 15, 2016·2 cites·18 claims
- 1484US10076567B2MPER-liposome conjugates and uses thereofUNIV DUKE·Filed 2014·Granted Sep 18, 2018·3 cites·31 claims
- 1584US10004800B2Antibody evolution immunogensUNIV DUKE·Filed 2013·Granted Jun 26, 2018·6 cites·24 claims
- 1683US9855329B2Mosaic HIV envelope immunogenic polypeptidesLOS ALAMOS NAT SECURITY LLC·Filed 2014·Granted Jan 2, 2018·5 cites·13 claims
- 1782US9844590B2Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogensLOS ALAMOS NAT SECURITY LLC·Filed 2015·Granted Dec 19, 2017·2 cites·9 claims
- 1882US9821053B2Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteinsUNIV DUKE·Filed 2015·Granted Nov 21, 2017·2 cites·18 claims
- 1981US10968255B2Compositions comprising HIV envelopes to induce CH235 lineage antibodiesUNIV DUKE·Filed 2017·Granted Apr 6, 2021·2 cites·16 claims
- 2081US7153509B2Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitopeUNIV CALFORINIA·Filed 2002·Granted Dec 26, 2006·19 cites·16 claims
- 2180US10010606B2Mosaic conserved region HIV immunogenic polypeptidesLOS ALAMOS NAT SECURITY LLC·Filed 2014·Granted Jul 3, 2018·2 cites·20 claims
- 2279US12364750B1Conserved region T cell vaccines for coronavirus and methods of useTRIAD NAT SECURITY LLC·Filed 2024·Granted Jul 22, 2025·0 cites·20 claims
- 2378US8460672B1Mosaic protein and nucleic acid vaccines against hepatitis C virusYUSIM KARINA·Filed 2010·Granted Jun 11, 2013·4 cites·5 claims
- 2476US10772952B2Antiviral vaccines with improved cellular immunogenicityBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2019·Granted Sep 15, 2020·0 cites·41 claims
- 2575US11331386B2Antiviral vaccines with improved cellular immunogenicityBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2020·Granted May 17, 2022·0 cites·27 claims
- 2675US11246920B2Compositions and methods for inducing HIV-1 antibodiesUNIV DUKE·Filed 2017·Granted Feb 15, 2022·2 cites·19 claims
- 2774US9844589B2Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responsesHAYNES BARTON F·Filed 2011·Granted Dec 19, 2017·2 cites·11 claims
- 2871US11628215B2HIV vaccines comprising one or more population episensus antigensVIR BIOTECHNOLOGY INC·Filed 2020·Granted Apr 18, 2023·0 cites·7 claims
- 2971US11554168B2HIV vaccines comprising one or more population episensus antigensVIR BIOTECHNOLOGY INC·Filed 2020·Granted Jan 17, 2023·0 cites·24 claims
- 3070US11230572B2Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the sameBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2017·Granted Jan 25, 2022·1 cites·30 claims
- 3169US12023376B1Conserved region T cell vaccines for coronavirus and methods of useTRIAD NAT SECURITY LLC·Filed 2021·Granted Jul 2, 2024·0 cites·15 claims
- 3267US11884704B2Compositions comprising HIV envelopes to induce CH235 lineage antibodiesUNIV DUKE·Filed 2021·Granted Jan 30, 2024·0 cites·15 claims
- 3367US11235055B2Nucleic acids encoding mosaic conserved region HIV immunogenic polypeptidesLOS ALAMOS NAT SECURITY LLC·Filed 2018·Granted Feb 1, 2022·0 cites·19 claims
- 3467US10946090B2Consensus/ancestral immunogensUNIV DUKE·Filed 2017·Granted Mar 16, 2021·0 cites·18 claims
- 3566US10849970B2Antibody evolution immunogensUNIV DUKE·Filed 2018·Granted Dec 1, 2020·0 cites·30 claims
- 3665US2016317648A1Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositionsUNIV DUKE·Filed 2014·Application pending·0 cites
- 3764US10426831B2Antiviral vaccines with improved cellular immunogenicityBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2017·Granted Oct 1, 2019·0 cites·40 claims
- 3863US2018185471A1Polyvalent vaccineUNIV DUKE·Filed 2017·Application pending·0 cites
- 3962US12485168B2Hepatitis B virus vaccinesVIR BIOTECHNOLOGY INC·Filed 2020·Granted Dec 2, 2025·0 cites·15 claims
- 4060US2021052720A1Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositionsUNIV DUKE·Filed 2020·Application pending·0 cites
- 4160US2025340598A1Compositions comprising v2 opt hiv envelopesUNIV DUKE·Filed 2022·Application pending·0 cites
- 4252US11773144B2Mosaic HIV-1 envelopes to induce ADCC responsesUNIV DUKE·Filed 2018·Granted Oct 3, 2023·0 cites·15 claims
- 4352US2011150915A1Polyvalent vaccineLOS ALAMOS NAT SECURITY LLC·Filed 2010·Application pending·0 cites
- 4451US10906941B2Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverageUNIV DUKE·Filed 2014·Granted Feb 2, 2021·0 cites·12 claims
- 4551US2023382952A1Compositions comprising hiv envelopes to induce hiv-1 antibodiesKORBER BETTE T·Filed 2021·Application pending·0 cites
- 4650US2003219452A1HIV envelope V3-CCR5 binding site immunogenFiled 2002·Application pending·0 cites
- 4747US2013273103A1Polyvalent immunogenLIAO HUA-XIN·Filed 2011·Application pending·0 cites
- 4846US10232034B2Compositions comprising CH505 envelopes, and trimersUNIV DUKE·Filed 2015·Granted Mar 19, 2019·0 cites·25 claims
- 4941US2018271973A1Compositions comprising ch505 envelopes, and trimers (eight valent hiv-1 composition and methods)UNIV DUKE·Filed 2015·Application pending·0 cites
- 5041US2017107260A1Mosaic hiv-1 sequences and uses thereofUNIV DUKE·Filed 2015·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →